Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/100940
Title: The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation
Author: Noriega, V.
Martínez-Laperche, C.
Buces, E.
Pion, M.
Sánchez-Hernández, N.
Martín-Antonio, B.
Guillem, V.
Bosch-Vizcaya, A.
Bento, L.
González-Rivera, M.
Balsalobre, P.
Kwon, M.
Serrano, D
Gayoso, J.
Cámara, R. de la
Brunet, Salut
Rojas-Contreras, R.
Nieto, J. B.
Martínez, C.
Gónzalez, M.
Espigado, I.
Vallejo, J. C.
Sampol, A.
Jiménez-Velasco, A.
Urbano Ispizua, Álvaro
Solano, C.
Gallardo, D.
Díez-Martín, J. L.
Buño, I.
Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
Keywords: Limfòcits
Cèl·lules T
Cèl·lules mare
Lymphocytes
T cells
Stem cells
Issue Date: 16-Oct-2015
Publisher: Public Library of Science (PLoS)
Abstract: The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (≤(GT)15) for the (GT)n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0140454
It is part of: PLoS One, 2015, vol. 10, num. 10
Related resource: http://dx.doi.org/10.1371/journal.pone.0140454
URI: http://hdl.handle.net/2445/100940
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
659974.pdf881.76 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons